AGIOS PHARMACEUTICALS, INC. Deferred Federal Income Tax Expense (Benefit)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-16.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2017-02-16
- AGIOS PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for the quarter ending 2012-12-31 was $1.92M.
- AGIOS PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for the quarter ending 2012-09-30 was $1.47M.
- AGIOS PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for the quarter ending 2012-06-30 was $1.78M.
- AGIOS PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2016 was $0.00.
- AGIOS PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2015 was $0.00.
- AGIOS PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- AGIOS PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2013 was $3.84M, a 42.72% decline from fiscal 2012.
| Period end | Deferred Federal Income Tax Expense (Benefit) 3 month | Deferred Federal Income Tax Expense (Benefit) 6 month | Deferred Federal Income Tax Expense (Benefit) 9 month | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-16 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-02-16 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-02-16 | |||
| 2013-12-31 | $3.84M 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $3.39M derived: sum of 2 quarters · filed 2015-02-24 | $5.17M derived: sum of 3 quarters · filed 2015-02-24 | $6.71M 10-K · filed 2015-02-24 |
| 2012-09-30 | $1.47M 10-Q · filed 2013-11-07 | $3.26M derived: sum of 2 quarters · filed 2013-11-07 | $4.79M 10-Q · filed 2013-11-07 | |
| 2012-06-30 | $1.78M 10-Q · filed 2013-09-05 | $3.32M 10-Q · filed 2013-09-05 | ||
| 2011-12-31 | -$10.66M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |